E2F1-regulated inhibitor of cell deathGenealiases: ERIC · LINC01130 · TCONS_00014875
Q-omics provides the consensus-scored ERICD profile across patient tissues and cancer cell-line models. ERICD expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, ERICD is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, ERICD RNA expression shows 16,694 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LGG, KIRP, and ACC as cancer lineages where ERICD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERICD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERICD survival associations across molecular data types. ERICD RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERICD RNA expression–survival associations across cancer types. High ERICD expression shows unfavorable associations in LGG, ACC, KIRP, LUSC, KIRC and STAD. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for ERICD RNA expression.
This table summarizes ERICD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ERICD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERICD shows higher tumor expression in KIRP, COAD, HNSC, THCA, LIHC and STAD. The KIRP box plot shows higher ERICD RNA expression in tumor versus normal tissue (log2 FC = +0.989, t-test p < 0.001).
This table shows molecular features associated with ERICD in patient tissues and cancer cell lines. In patient samples, ERICD shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
